References
- S. Sundaran, A. Udayan, K. Hareendranath, B. Eliyas, B. Ganesan, A. Hassan, R. Subash, V. Palakkal and M. S. Salahudeen, Study on the classification, causality, preventability and severity of adverse drug reaction using spontaneous reporting system in hospitalized patients, Pharmacy 6(4) (2018) Article ID 108 (9 pages); https://doi.org/10.3390/pharmacy6040108
- O. Laatikainen, S. Sneck and M. Turpeinen, Medication-related adverse events in health care—what have we learned? A narrative overview of the current knowledge, Eur. J. Clin. Pharmacol.78 (2022) 159–170; https://doi.org/10.1007/s00228-021-03213-x
- J. J. Coleman and S. K. Pontefract, Adverse drug reactions, Clin. Med. 16(5) (2016) 481–485; https://doi.org/10.7861/clinmedicine.16-5-481
- A. M. Schurig, M. Böhme, K. S. Just, C. Scholl, H. Dormann, B. Plank-Kiegele, T. Seufferlein, I. Gräff, M. Schwab and J. C. Stingl, Adverse drug reactions (ADR) and emergencies-the prevalence of suspected ADR in four emergency departments in Germany, Dtsch. Arztebl. Int. 115 (2018) 251–258; https://doi.org/10.3238/arztebl.2018.0251
- T. M. Yadesa, F. E. Kitutu, S. Deyno, P. E. Ogwang, R. Tamukong and P. E. Alele, Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: A systematic review and meta-analysis, SAGE Open Med. 9 (2021) 1–14; https://doi.org/10.1177/20503121211039099
- T. M. Alhawassi, I. Krass, B. Bajorek and L. G. Pont, A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting, Clin. Interv. Aging 9 (2014) 2079–2086; https://doi.org/10.2147/CIA.S71178
- M. Kauppila, J. T. Backman, M. Niemi and O. Lapatto-Reiniluoto, Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department, Eur. J. Clin. Pharmacol. 77 (2021) 643–650; https://doi.org/10.1007/s00228-020-03043-3
- C. Pedrós, F. Formiga, X. Corbella and J. M. Arnau, Adverse drug reactions leading to urgent hospital admission in an elderly population: Prevalence and main features, Eur. J. Clin. Pharmacol. 72 (2016) 219–226.; https://doi.org/10.1007/s00228-015-1974-0
- J. Ma, Y. Wang, M. Gao, Q. Meng and J. Liu, Adverse drug reactions as the cause of emergency department admission of patients aged 80 years and older, Eur. J. Intern. Med. 23(6) (2012) e162-e163; https://doi.org/10.1016/j.ejim.2012.05.004
- N. Fokter, M. Možina and M. Brvar, Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments, Wiener Klin. Wochenschr. 122 (2010) 81–88; https://doi.org/10.1007/s00508-009-1251-2
- S. K. Behera, S. Das, A. S. Xavier, S. Velupula and S. Sandhiya, Comparison of different methods for causality assessment of adverse drug reactions, Int. J. Clin. Pharm. 40 (2018) 903–910; https://doi.org/10.1007/s11096-018-0694-9
- S. Pande, Causality or relatedness assessment in adverse drug reaction and its relevance in dermatology, Indian J. Dermatol. 63(1) (2018) 18–21; https://doi.org/10.4103/IJD.IJD_579_17
- The Uppsala Monitoring Centre. The Use of the WHO-UMC System for Standardised Case Causality Assessment, June 2013; https://www.who.int/publications/m/item/WHO-causality-assessment; last access date November 10, 2022.
- C. A. Naranjo, U. Busto, E. M. Sellers, P. Sandor, I. Ruiz, E. A. Roberts, E. Janacek, C. Domecq and D. J. Greenblatt, A method for estimating the probability of adverse drug reactions, Clin. Pharmacol. Ther. 30 (1981) 239–245; https://doi.org/10.1038/CLPT.1981.154
- T. J. Oscanoa, F. Lizaraso and A. Carvajal, Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis, Eur. J. Clin. Pharmacol. 73 (2017) 759–770; https://doi.org/10.1007/s00228-017-2225-3
- K. S. Just, H. Dormann, M. Schurig, M. Böhme, M. Steffens, B. Plank-Kiegele, K. Ettrich, T. Seufferlein, I. Gräff, S. Igel, S. Schricker, S. U. Jaeger, M. Schwab and J. C. Stingl, The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study, Br. J. Clin. Pharmacol. 86 (2020) 2144–2154; https://doi.org/10.1111/bcp.14304
- M. Kyonen, I. Folatre, X. Lagos and S. Vargas, Comparison of two methods to assess causality of adverse drug reactions, Rev. Med. Chile 143(7) (2015) 880–886; https://doi.org/10.4067/s0034-98872015000700009
- L. Magro, E. Arzenton, R. Leone, M. G. Stano, M. Vezzaro, A. Rudolph, I. Castagna and U. Moretti, Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database, Front. Pharmacol. 11 (2021) Article ID 622862 (9 pages); https://doi.org/10.3389/fphar.2020.622862
- T. N. G. de Andrade Santos, G. M. da Cruz Macieira, B. M. C. Sodré Alves, T. Onozato, G. C. Cardoso, M. T. F. Nascimento, P. R. S. Martins-Filho, D. P. de Lyra, Jr. and A. D. de Oliveira Filho, Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis, PLoS ONE 15(7) (2020) e0235353 (14 pages); https://doi.org/10.1371/journal.pone.0235353
- P. Olivier, L. Bertrand, M. Tubery, D. Lauque, J. L. Montastruc and M. Lapeyre-Mestre, Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: A prospective survey, Drugs Aging 26 (2009) 475–482; https://doi.org/10.2165/00002512-200926060-00004
- C. Bucşa, A. Farcaş, I. Cazacu, D. Leucuta, A. Achimas-Cadariu, C. Mogosan and M. Bojita, How many potential drug-drug interactions cause adverse drug reactions in hospitalized patients?, Eur. J. Intern. Med. 24 (2013) 27–33; https://doi.org/10.1016/j.ejim.2012.09.011
- L. M. De Oliveira, J. D. A. C. Diel, A. Nunes and T. Da Silva Dal Pizzol, Prevalence of drug interactions in hospitalised elderly patients: A systematic review, Eur. J. Hosp. Pharm. 28 (2021) 4–9; https://doi.org/10.1136/ejhpharm-2019-002111
- Official Gazette of the Republic of Slovenia, No. 17/14 and 66/19, Medicinal Products Act, http://www.pisrs.si/Pis.web/pregledPredpisa?id=ZAKO6295; last access date November 9, 2022.
- Official Gazette of the Republic of Slovenia, No. 57/14 and 27/17, Rules on Pharmacovigilance of Medicinal Products for Human Use; http://www.pisrs.si/Pis.web/pregledPredpisa?id=PRAV12129; last access date November 9, 2022.
- U. S. Department of Health and Human Services, Common Terminology Criteria for Adverse Events (CTCAE) – Version 5.0, Nov 27, 2017; https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf; last visit November 9, 2022
- S. Gautron, J. Wentzell, S. Kanji, T. Nguyen, D. M. Kobewka and E. MacDonald, Characterization of serious adverse drug reactions in hospital to determine potential implications of mandatory reporting, Can. J. Hosp. Pharm. 71 (2018) 316–323.
- S. L. Chan, X. Ang, L. L. Sani, H. Y. Ng, M. D. Winther, J. J. Liu, L. R. Brunham and A. Chan, Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study, Br. J. Clin. Pharmacol. 82 (2016) 1636–1646; https://doi.org/10.1111/bcp.13081
- S. Dechanont, S. Maphanta, B. Butthum and C. Kongkaew, Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis, Pharmacoepidemiol. Drug Saf. 23 (2014) 489–497; https://doi.org/10.1002/pds
- H. Murayama, M. Sakuma, Y. Takahashi and T. Morimoto, Improving the assessment of adverse drug reactions using the Naranjo algorithm in daily practice: The Japan adverse drug events study, Pharmacol. Res. Perspect. 6(1) (2018) e00373 (7 pages); https://doi.org/10.1002/prp2.373
- A. Ghosh, A. Hegde, S. Grover, Mirtazapine-associated hyponatremia presenting as delirium, Indian J. Pharmacol. 46(4) (2014) 448–449; https://doi.org/10.4103/0253-7613.135964
- E. Tantisattamo, A. Chokechanachaisakul, S. Pitukweerakul, P. Ratanasrimetha, P. Shrivastava and D. Samarapungavan, Calcineurin inhibitor-induced hyperkalemia and salt-sensitive hypertension in early post-kidney transplant period, FASEB J. 30(S1) (2016) 916.19-916.19; https://doi.org/10.1096/fasebj.30.1_supplement.916.19
- M. A. Raebel, Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, Cardiovasc. Ther. 30(3) (2012) e156–e166; https://doi.org/10.1111/j.1755-5922.2010.00258.x
- M. Becker, M. Kallewaard, P. W. J. Caspers, L. E. Visser, H. G. M. Leufkens and B. H. Ch. Stricker, Hospitalisations and emergency department visits due to drug-drug interactions: a literature review, Pharmacoepidemiol. Drug Saf. 16(6) (2007) 641–651; https://doi.org/10.1002/pds.1351
- W. Y. Zheng, L. C. Richardson, L. Li, R. O. Day, J. I. Westbrook and M. T. Baysari, Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis, Eur. J. Clin. Pharmacol. 74 (2018) 15–27; https://doi.org/10.1007/S00228-017-2357-5
- N. Muhič, A. Mrhar and M. Brvar, Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: a prospective cohort study, Eur. J. Clin. Pharmacol. 73 (2017) 875–882; https://doi.org/10.1007/s00228-017-2232-4
- A. J. Karter, Role of self-monitoring of blood glucose in glycemic control, Endocr. Pract. 12(Suppl. 1) (2006) 110–117; https://doi.org/10.4158/EP.12.S1.110
- E. Espinel, J. Joven, I. Gil, P. Suñé, B. Renedo, J. Fort and D. Serón, Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study, BMC Res. Notes 6 (2013) Article ID 306 (9 pages); https://doi.org/10.1186/1756-0500-6-306
- C. Bhanu, D. Nimmons, I. Petersen, M. Orlu, D. Davis, H. Hussain, S. Magammanage and K. Walters, Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials, PLoS Med. 18(11) (2021) e1003821 (14 pages); https://doi.org/10.1371/journal.pmed.1003821
- A.S. Abuzour, G. Hoad-Reddick, M. Shahid, D. T. Steinke, M. P. Tully, S. D. Williams and P. J. Lewis, Patient prioritisation for hospital pharmacy services: current approaches in the UK, Eur. J. Hosp. Pharm. 28(Suppl. 2) (2021) e102–e108; https://doi.org/10.1136/ejhpharm-2020-002365
- L. Létinier, A. Ferreira, A. Marceron, M. Babin, J. Micallef, G. Miremont-Salamé and A. Pariente, Spontaneous reports of serious adverse drug reactions resulting from drug–drug interactions: An analysis from the French pharmacovigilance database, Front. Pharmacol. 11 (2021) Article ID 624562 (8 pages); https://doi.org/10.3389/fphar.2020.624562
- M. Lucic, P. Milosević, B. N. Martić, M. M. Paut-Kusturica, M. Jovančević, B. M. Ubavić, B. Todorovic, J. D. Krajačić and L. A. Rašković, The role of a pharmacist in pharmacovigilance system, J. Hosp. Pharmacol. 5(3) (2018) 715–727; https://doi.org/10.5937/HPIMJ1803715L
- S. L. Gray, L. A. Hart, S. Perera, T. P. Semla, K. E. Schmader and J. T. Hanlon, Meta-analysis of interventions to reduce adverse drug reactions in older adults, J. Am. Geriatr. Soc. 66(2) (2018) 282–288; https://doi.org/10.1111/jgs.15195